纳武单抗治疗肾细胞癌：最新证据与临床潜力
Nivolumab in renal cell carcinoma: latest evidence and clinical potential.
作者信息
Mazza Camille, Escudier Bernard, Albiges Laurence
机构信息
Department of Medical Oncology, Gustave Roussy, Villejuif, France.
Département de médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
出版信息
Ther Adv Med Oncol. 2017 Mar;9(3):171-181. doi: 10.1177/1758834016679942. Epub 2016 Dec 11.
Abstract
Similar to melanoma, renal cell carcinoma (RCC) has been historically considered as an immunogenic tumor, with interleukin 2 (IL-2) and interferon alpha (IFN-α) being the first approved treatments in the 1990s. However, these therapies were effective in only 10-20% of cases and were not well tolerated. Recently, new insights on the interaction between the immune system and tumor have identified the programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway to be a key player in evading host immune responses. The strategy of immune checkpoint blockade is to reduce inhibitory signaling and restore the patient's natural tumor-specific T-cell-mediated immune responses. Nivolumab is the first PD-1 inhibitor to have gained approval for the treatment of patients with metastatic melanoma, squamous and nonsquamous non-small cell lung cancer (NSCLC), Hodgkin disease and recently RCC. In this review, we discuss results from studies of nivolumab in RCC, clinical experience with this agent, and its future development.
摘要
与黑色素瘤相似，肾细胞癌（RCC）在历史上一直被视为一种免疫原性肿瘤，白细胞介素2（IL-2）和干扰素α（IFN-α）是20世纪90年代首批获批的治疗药物。然而，这些疗法仅在10%-20%的病例中有效，且耐受性不佳。最近，关于免疫系统与肿瘤相互作用的新见解表明，程序性死亡1/程序性死亡配体1（PD-1/PD-L1）通路是逃避宿主免疫反应的关键因素。免疫检查点阻断策略是减少抑制性信号传导并恢复患者天然的肿瘤特异性T细胞介导的免疫反应。纳武单抗是首个获批用于治疗转移性黑色素瘤、鳞状和非鳞状非小细胞肺癌（NSCLC）、霍奇金病以及最近用于治疗肾细胞癌患者的PD-1抑制剂。在本综述中，我们讨论了纳武单抗治疗肾细胞癌的研究结果、使用该药物的临床经验及其未来发展。
相似文献
1
Nivolumab in renal cell carcinoma: latest evidence and clinical potential.纳武单抗治疗肾细胞癌：最新证据与临床潜力
Ther Adv Med Oncol. 2017 Mar;9(3):171-181. doi: 10.1177/1758834016679942. Epub 2016 Dec 11.
2
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
3
Nivolumab in NSCLC: latest evidence and clinical potential.纳武利尤单抗治疗非小细胞肺癌：最新证据和临床潜力。
Ther Adv Med Oncol. 2015 Mar;7(2):85-96. doi: 10.1177/1758834014567470.
4
Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.多原发恶性肿瘤患者对免疫检查点抑制剂（ICI）治疗的不同反应：机器人辅助部分肾切除术（RP）后出现的 PD-L1 阴性输尿管和肺转移的透明细胞肾细胞癌，对 ICI 治疗后进展，而同步 PD-L1 阳性原发性肺鳞癌对 ICI 治疗反应良好：病例报告。
World J Surg Oncol. 2023 Feb 6;21(1):37. doi: 10.1186/s12957-023-02920-2.
5
Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.纳武单抗治疗晚期肾细胞癌：临床试验证据与经验
Ther Adv Urol. 2016 Oct;8(5):319-326. doi: 10.1177/1756287216656811. Epub 2016 Jul 7.
6
Nivolumab - Pearls of Evidence.纳武利尤单抗——证据精粹
Indian J Med Paediatr Oncol. 2017 Oct-Dec;38(4):520-525. doi: 10.4103/ijmpo.ijmpo_193_16.
7
Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.纳武单抗进行的检查点免疫疗法用于治疗转移性黑色素瘤。
J Cancer Res Ther. 2018 Oct-Dec;14(6):1167-1175. doi: 10.4103/jcrt.JCRT_1290_16.
8
The next generation of immunotherapy: keeping lung cancer in check.下一代免疫疗法：控制肺癌
J Hematol Oncol. 2017 Apr 24;10(1):87. doi: 10.1186/s13045-017-0456-5.
9
Nivolumab in renal cell carcinoma.纳武单抗用于治疗肾细胞癌。
Expert Opin Biol Ther. 2015 Jul;15(7):1049-60. doi: 10.1517/14712598.2015.1049596. Epub 2015 Jun 3.
10
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.美国食品药品监督管理局批准摘要：纳武单抗用于治疗在铂类化疗期间或之后病情进展的转移性非小细胞肺癌。
Oncologist. 2016 May;21(5):634-42. doi: 10.1634/theoncologist.2015-0507. Epub 2016 Mar 16.
引用本文的文献
1
IL1A: a novel prognostic biomarker and potential therapeutic target for renal clear cell carcinoma.白细胞介素1α：肾透明细胞癌的一种新型预后生物标志物及潜在治疗靶点。
Oncol Res. 2025 Jun 26;33(7):1739-1755. doi: 10.32604/or.2025.061978. eCollection 2025.
2
Kidney Injury Molecule-1 Expression in Pathological T1b Clear Cell Renal Cell Carcinoma: A Putative Biomarker of High Immune-Inflamed Status and Recurrence.肾损伤分子-1在病理T1b期透明细胞肾细胞癌中的表达：一种高免疫炎症状态和复发的潜在生物标志物
Pathol Int. 2025 Jul;75(7):340-348. doi: 10.1111/pin.70024. Epub 2025 May 14.
3
Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature.肿瘤免疫治疗与免疫制品应用：文献综述。
J Immunol Res. 2024 Oct 24;2024:8481761. doi: 10.1155/2024/8481761. eCollection 2024.
4
Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors.PD-1/PD-L1 抑制剂在治疗泌尿系统肿瘤中的研究进展。
Curr Cancer Drug Targets. 2024;24(11):1104-1115. doi: 10.2174/0115680096278251240108152600.
5
A novel coagulation-related lncRNA predicts the prognosis and immune of clear cell renal cell carcinoma.一种新型与凝血相关的长链非编码 RNA 可预测透明细胞肾细胞癌的预后和免疫情况。
Sci Rep. 2023 Sep 28;13(1):16302. doi: 10.1038/s41598-023-43065-2.
6
Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy.PD-1/PD-L1阻断疗法治疗肾细胞癌（RCC）的临床潜力：一种快速发展的策略。
Cancer Cell Int. 2022 Dec 12;22(1):401. doi: 10.1186/s12935-022-02816-3.
7
CDCA3 Predicts Poor Prognosis and Affects CD8 T Cell Infiltration in Renal Cell Carcinoma.CDCA3预测肾细胞癌预后不良并影响CD8 T细胞浸润
J Oncol. 2022 Sep 28;2022:6343760. doi: 10.1155/2022/6343760. eCollection 2022.
8
CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.CC-01（西达本胺联合塞来昔布）通过调节肿瘤免疫微环境，与免疫检查点抑制剂联合减少肿瘤进展。
Sci Rep. 2022 Jan 20;12(1):1100. doi: 10.1038/s41598-022-05055-8.
9
Renal Toxicity.肾毒性。
Adv Exp Med Biol. 2021;1342:389-397. doi: 10.1007/978-3-030-79308-1_16.
10
Extramammary Paget's Disease: Diagnosis, Pathogenesis, and Treatment with Focus on Recent Developments.乳房外 Paget 病：诊断、发病机制和治疗，重点关注最新进展。
Curr Oncol. 2021 Aug 5;28(4):2969-2986. doi: 10.3390/curroncol28040260.
本文引用的文献
1
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.纳武利尤单抗治疗转移性肾细胞癌患者超过进展期的安全性和疗效：一项随机临床试验的亚组分析。
JAMA Oncol. 2016 Sep 1;2(9):1179-86. doi: 10.1001/jamaoncol.2016.0775.
2
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.纳武单抗在转移性肾细胞癌中的免疫调节活性。
Clin Cancer Res. 2016 Nov 15;22(22):5461-5471. doi: 10.1158/1078-0432.CCR-15-2839. Epub 2016 May 11.
3
Anti-programmed Death Receptor 1 Blockade Induces Clinical Response in a Patient With Metastatic Collecting Duct Carcinoma.抗程序性死亡受体1阻断剂在一名转移性集合管癌患者中诱导临床反应。
Clin Genitourin Cancer. 2016 Aug;14(4):e431-4. doi: 10.1016/j.clgc.2016.02.013. Epub 2016 Feb 23.
4
Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis.程序性死亡配体-1（PD-L1）在肾细胞癌中的临床病理及预后价值：一项荟萃分析
Int J Clin Exp Med. 2015 Sep 15;8(9):14595-603. eCollection 2015.
5
Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.抗 PD-1/PD-L1 治疗转移性肾细胞癌的放射异质性反应。
Cancer Immunol Res. 2016 Jan;4(1):12-7. doi: 10.1158/2326-6066.CIR-15-0197. Epub 2015 Nov 20.
6
Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.更新的透明细胞肾细胞癌患者在接受 VEGF 靶向治疗失败后的 EAU 指南。
Eur Urol. 2016 Jan;69(1):4-6. doi: 10.1016/j.eururo.2015.10.017. Epub 2015 Oct 24.
7
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.卡博替尼与依维莫司治疗晚期肾细胞癌的疗效对比
N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.
8
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.纳武单抗与依维莫司治疗晚期肾细胞癌的比较
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
9
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.SWITCH 研究：比较索拉非尼-舒尼替尼与舒尼替尼-索拉非尼序贯治疗转移性肾细胞癌的随机、开放标签、连续研究
Eur Urol. 2015 Nov;68(5):837-47. doi: 10.1016/j.eururo.2015.04.017. Epub 2015 May 4.
10
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.比较研究：舒尼替尼或帕唑帕尼治疗的肾细胞癌患者的 PD-L1 肿瘤表达与治疗结果的相关性：一项随机对照试验的结果。
Clin Cancer Res. 2015 Mar 1;21(5):1071-7. doi: 10.1158/1078-0432.CCR-14-1993. Epub 2014 Dec 23.
Zotero 插件